Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04771507

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Ibrutinib, an inhibitor of Bruton´s tyrosine kinase (BTK) is approved in CLL as continuous, daily administration of 420 mg orally until progression. Ibrutinib drug costs in health care are rapidly increasing and are difficult to predict, as long-term follow up analyses have shown that many patients remain on therapy for several years, in some cases even many years. It has been observed that patients who stop ibrutinib due to side effects may often remain with continued CLL disease control i.e. in stable partial remission even when off ibrutinib therapy. There are also emerging data on mutations within BTK, with loss of efficacy of ibrutinib, during long-term continuous administration. These observations raise the question whether alternative dosing strategies may be feasible. This pilot study will explore intermittent and repeated dosing of ibrutinib, until alternative therapy is required due to resistance or intolerance to ibrutinib. An "ON-OFF" dosing strategy will be applied, where advanced-phase CLL patients who have received at least 6 months of ibrutinib and who have achieved a stable PR will stop ibrutinib and be followed off therapy until clinical progression, at which ibrutinib will be re-instituted. Such "ON-OFF" ibrutinib cycles may be repeated until non-tolerability or resistance, or need of continuous dosing of ibrutinib (i.e. early progression when off the drug). If successful, the study will indicate a way forward towards reducing ibrutinib drug costs in health care without affecting long-term disease control, possibly also with fewer ibrutinib-related side effects due to a lower cumulative dose of ibrutinib. Long-term effects on potential mutations within BTK and its downstream signaling molecules will also be analysed.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Chronic Lymphocytic Leukemia Chronic Disease Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms Small Lymphocytic Lymphoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

St Olavs Hospital, Trondheim, Norway

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to understand and voluntarily provide written informed consent and comply with the requirements of the study.
  • Age 18 years and older. There is no upper age limit in this trial.
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Before start ibrutinib for the first time: diagnosed with CLL/SLL and active disease in need of treatment after having failed chemoimmunotherapy for CLL defined as a) refractory according to iwCLL criteria; or b) relapsed and deemed not suitable for additional chemo- or chemoimmunotherapy or c) del 17p and/or TP53 mutation irrespective of prior therapy.
  • Having received at least 6 months of ibrutinib therapy and having achieved at least clinical PR according to IWCLL criteria.
  • ECOG performance status of </= 2 at screening.
  • Laboratory test results:
  • Absolute neutrophil count >/= 0.5 x 109/L
  • Platelet count >/= 30 x 109/L
  • Serum creatinine < 177 µmol/L
  • ASAT (SGOT) and ALAT (SGPT) >/= 2 x ULN or >/= 5 x ULN unless attributable to CLL/SLL
  • Disease free of prior malignancies for >/= 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
  • Agree to use reliable forms of contraception. Post-menopausal females and surgically sterilized females are exempt from this criterion.

Exclusion criteria

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  • Pregnant or breast feeding females.
  • Any condition, including the presence of laboratory abnormalities, which according to the responsible physician places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Use of any other experimental therapy within the last 14 days.
  • Concurrent use of other anti-cancer agents or treatments than ibrutinib (except a low dose of corticosteroids, max 10 mg of prednisone/day).
  • Positivity for HIV or infectious hepatitis, type A, B or C.
  • Opportunistic infections within the last 3 months.
  • Patient planned for or being a potential candidate for allo-SCT.
  • Uncontrolled hemolytic anemia or autoimmune thrombocytopenia.
  • CNS involvement or history of Richter's transformation.
  • Requires or has received anticoagulation treatment with warfarin or equivalent Vitamin K antagonists (eg, phenprocoumon) within 28 days of the first dose of ibrutinib.
  • Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor.

Treatment and study plan

Ibrutinib

Drug

Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.

Other names: Imbruvica

Primary outcomes

  1. Safety measured as type, frequency and severity of adverse events.

    Time frame: Through study completion, 1-24 months.

    Type, frequency and severity of adverse events and relationship to intermittent ibrutinib dosing.

Secondary outcomes

  1. Overall response at each treatment cycle.

    Time frame: Through study completion, 1-24 months.

    Response when re-starting ibrutinib, at each cycle.

  2. Time to PR and PR-L at each cycle.

    Time frame: Through study completion, 1-24 months.

    Time to partial response (PR) and partial response with persistent lymphocytosis (PR-L) when re-starting ibrutinib, at each cycle.

  3. Time to stop until restart of ibrutinib due to progress

    Time frame: Through study completion, 1-24 months.

    Time from the patient going off ibrutinib until it has to be re-started due to progressive, for each cycle.disease (PD), at each cycle.

  4. Number of ibrutinib treatment cycles and OFF therapy periods.

    Time frame: Through study completion, 1-24 months.

    The number of cycles each patient stop and re-start ibrutinib.

  5. Cumulative dose of ibrutinib.

    Time frame: Through study completion, 1-24 months.

    The cumulative dose of ibrutinib for each patient.

  6. Overall survival.

    Time frame: Through study completion, 1-24 months.

    Overall survival.

  7. Risk of early rebound phenomenon.

    Time frame: Through study completion, 1-24 months.

    Observation of early rebound phenomemon at each re-start of ibrutinib.

  8. Time to need of alternative treatment.

    Time frame: Through study completion, 1-24 months.

    Time to need of alternative treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Jeanette Lundin, MD PhD

CONTACT

[email protected]

0700 85 67 86 ext. 46

Sanna Nyström, PhD

CONTACT

[email protected]

08 517 759 27 ext. 46

Sponsors and collaborators

Lead sponsor

Jeanette Lundin

Other

Registry information

Official study title

A Pilot Study on Intermittent and Repeated Dosing of Ibrutinib in the Treatment of Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Acronym: IbruOnOff

Important dates

Study start
2018
Primary completion
2023
Study completion
2027
First posted
Feb 25, 2021
Registry last updated
Feb 25, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.